Table 2.

Factors affecting the progression-free survival and overall survival in patients after anti-PD-1 therapy based on multivariate analysis.

Variable	Category	Multivariate survival analysis Progression-free survival			Multivariate survival analysis Overall survival
		AHR	95% CI	P	AHR	95% CI	P
Age (years)	≥65 vs. <65	1.273	0.709–2.284	0.419	1.147	0.629–2.092	0.655
Sex	Women vs. Men	0.812	0.428–1.540	0.523	1.127	0.569–2.233	0.732
EGFR status	Mutant vs. wild-type	2.158	0.954–4.882	0.065	2.563	1.083–6.063	0.032
PD-L1	≥ 1% vs. <1%	0.878	0.505–1.528	0.646	0.689	0.375–1.264	0.228
NMR	≥ 5.75% vs. <5.75	0.198	0.095–0.413	0.0001	0.369	0.190–0.719	0.003

Abbreviations: EGFR, epidermal growth factor receptor; NMR, NK cells to Lox-1⁺PMN-MDSC ratio; AHR, adjusted hazard ratio; CI, confidence interval.